Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HALT: SBRT with or without continued TKI in oligo-progressive NSCLC
NCT03256981Phase 3Active, not recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Nov 2017
- Primary completion
- Jul 2023
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The Institute of Cancer Research. Primary endpoint: Progression free survival up to 24 months. Started Nov 2017; status: active, not recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03256981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03256981.